Actinium's ATNM — 400 Shows Antitumor Activity in Preclinical Lung Cancer Models
Actinium Pharmaceuticals reported preclinical antitumor activity for ATNM-400, its actinium-225 radiotherapy, across lung, colorectal and ovarian cancer models. In non-small cell lung cancer, ATNM-400 showed standalone activity and enhanced responses with KRAS or ALK inhibitors, including in resistant models. Colorecta